

## Special Issue

# Advances in Combination Therapy for Chronic Diseases: Bridging Conventional and Natural Products for Enhanced Outcomes

### Message from the Guest Editor

Chronic diseases, such as cardiovascular diseases, diabetes, arthritis, and neurodegenerative disorders, pose significant global health challenges due to their prolonged nature and the complexity of their underlying mechanisms, including chronic inflammation, oxidative stress, and immune dysregulation. While conventional pharmaceutical therapies play a crucial role in managing these conditions, long-term use often leads to side effects, drug resistance, and incomplete treatment efficacy.

This Special Issue will explore the growing interest in combination therapy, including the integration of natural products (i.e., crude herbal medicine or isolated/purified natural products) and natural products with conventional drugs, to enhance therapeutic outcomes, reduce adverse effects, and offer a more holistic approach to chronic disease management. This Special Issue will highlight innovative research, clinical trials, and mechanistic studies that examine the enhanced (i.e., synergistic, additive) effects of natural products and drug–natural product combinations, their molecular targets, and the potential for personalized medicine.

### Guest Editor

Dr. Xian (Phoebe) Zhou

NICM Health Research Institute, Western Sydney University,  
Westmead, NSW 2145, Australia

### Deadline for manuscript submissions

31 January 2026



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/222447](https://mdpi.com/si/222447)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).